儿童肺炎支原体23S rRNA基因位点突变检测分析

目的了解儿童肺炎支原体(MP)大环内酯类耐药基因(23SrRNA)位点突变,以及与临床资料的相关性。方法收集该院354份肺炎患儿的呼吸道标本,采用实时荧光定量PCR法检测MP及23SrRNA位点突变(A2063G或/和A2064G)情况,并将MP阳性患儿分成位点突变组和未突变组,比较两组之间的临床资料。结果 354份呼吸道标本中,166份检测为MP阳性(46.9%),且135份MP阳性标本中存在23SrRNA基因位点突变(阳性检出率81.3%),31份未检测到23SrRNA基因位点突变。分析突变组和非突变组的临床资料发现两组在年龄和性别方面比较差异无统计学意义(P0.05),但突变组的重症肺炎和肺外并发症发生率高于未突变组(P0.05),且平均住院时间和平均发热时间均较未突变组长(P0.05)。结论 MP 23SrRNA基因位点突变的较高检出率提示MP对大环内酯类耐药率较高,这为临床MP的感染、治疗提供一定的参考依据。     

Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation

A total of 195 Mycoplasma pneumoniae strains were isolated from 2,462 clinical specimens collected between April 2002 and March 2004 from pediatric outpatients with respiratory tract infections. Susceptibilities to six macrolide antibiotics (ML), telithromycin, minocycline, levofloxacin, and sitafloxacin were determined by the microdilution method using PPLO broth. A total of 183 M. pneumoniae isolates were susceptible to all agents and had excellent MIC90s in the following order: 0.00195 microg/ml for azithromycin and telithromycin, 0.0078 microg/ml for clarithromycin, 0.0156 microg/ml for erythromycin, 0.0625 microg/ml for sitafloxacin, 0.5 microg/ml for minocycline, and 1 microg/ml for levofloxacin. Notably, 12 ML-resistant M. pneumoniae strains were isolated from patients with pneumonia (10 strains) or acute bronchitis (2 strains). These strains showed resistance to ML with MICs of >or=1 microg/ml, except to rokitamycin. Transition mutations of A2063G or A2064G, which correspond to A2058 and A2059 in Escherichia coli, in domain V on the 23S rRNA gene in 11 ML-resistant strains were identified. By pulsed-field gel electrophoresis typing, these strains were classified into groups I and IIb [corrected] as described previously (A. Cousin-Allery, A. Charron, B. D. Barbeyrac, G. Fremy, J. S. Jensen, H. Renaudin, and C. Bebear, Epidemiol. Infect. 124:103-111, 2000). These findings suggest that excessive usage of MLs acts as a trigger to select mutations on the corresponding 23S rRNA gene with the resultant occurrence of ML-resistant M. pneumoniae. Monitoring ML susceptibilities for M. pneumoniae is necessary in the future.     

肺炎链球菌对大环内酯类抗生素耐药情况及耐药基因研究

目的调查上海地区肺炎链球菌对红霉素的敏感度，研究肺炎链球菌对大环内酯类抗生素耐药机制。方法对中山医院57株临床分离肺炎链球菌进行红霉素药敏试验；应用聚合酶链反应（PCR）技术对上海4所医院中分离的53株红霉素耐药肺炎链球菌检测耐药基因（ermB，mefA，merE）。结果57株肺炎链球菌中12株（21．0％）敏感，3株（5．3％）中介，42株（73．7％）耐药。53株红霉素耐药肺炎链球菌中，ermB基因、mere基因、mefA基因分别在51株（96．2％）、22株（41．5％）和1株（1．9％）中检测到。其中21株（39．6％）同时检测到ermB基因和mefE基因，1株（1．9％）同时检测到ermB基因和mefA基因，1株（1．9％）未检测到ermB基因、mefE基因或mefA基因。结论上海地区肺炎链球菌对大环内酯类抗生素耐药率较高。ErmB介导的靶位改变是最常见的耐药机制，mef（特别是mefE）介导外排机制引起者也较常见。     

Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare.

Clarithromycin is a potent macrolide that has been used for treating infections with nontuberculous mycobacteria. Pairs of susceptible and resistant Mycobacterium intracellulare strains were obtained from patients with chronic pulmonary M. intracellulare infections undergoing monotherapy with clarithromycin. Nucleotide sequence comparisons of the peptidyltransferase region in 23S rRNAs from parental and resistant strains revealed that in three of six resistant strains, for which the MIC was > 32 micrograms/ml, a single base was mutated (Escherichia coli equivalent, A-2058-->G, C, or U). As the modification of adenine 2058 by dimethylation is a frequent cause of macrolide resistance in a variety of different bacteria, we suggest that mutation of A-2058 confers acquired resistance to clarithromycin in M. intracellulare.     

Streptococcus pyogenes isolates with high-level macrolide resistance and reduced susceptibility to telithromycin associated with 23S rRNA mutations

Seven high-level macrolide-resistant Streptococcus pyogenes isolates had reduced activity to telithromycin but were negative for methylation and efflux genes. All were of the constitutive phenotype, were clonally related (emm type 12 and MLST type 36), and had identical dual mutations (A2058G and U2166C) in domain V of 23S rRNA.     

Antimicrobial activity and spectrum of sparfloxacin tested against erythromycin-resistant Streptococcus pneumoniae isolates

Recognition of a worldwide increase of penicillin-resistant Streptococcus pneumoniae and cross-resistance to other classes of antimicrobials have placed a great urgency on the need for new antimicrobial agents. Sparfloxacin, a novel pyridone carboxylic acid fluoroquinolone derivative was evaluated and compared to six other compounds for antimicrobial activity against erythromycin-resistant pneumococci (50 strains). The Etest susceptibility testing method was used to inoculate Mueller-Hinton agar supplemented with 5% sheep blood. There was extensive cross-resistance between erythromycin, clarithromycin (94%), and azithromycin (100%), but no cross-resistance was detected between macrolides/azalides and sparfloxacin (all strains susceptible at ⩽1.0 μg/ml). Sparfloxacin (MIC₉₀, 1 μg/ml) was four-fold more active than ciprofloxacin and ofloxacin (MIC₉₀, 4 μg/ml). Sparfloxacin appears to possess excellent in vitro activity against erythromycin-resistant S. pneumoniae that were often highly resistant to beta-lactams, and further studies are recommended to investigate its in vivo efficacy against these multi-resistant organisms.     

Predominance of 23S rRNA mutants among non-erm, non-mef macrolide-resistant clinical isolates of Streptococcus pneumoniae collected in the United States in 1999-2000

A total of 322 erythromycin-resistant pneumococci from TRUST 3 and TRUST 4 United States surveillance studies (1999-2000) were screened for 23S rRNA, L4, and L22 gene mutations. Nineteen isolates, two with mefA, had mutations at position 2058 or 2059 in 23S rRNA. Two had a 69GTG71-to-TPS substitution in L4; one of these also contained ermA.     

Interaction of avilamycin with ribosomes and resistance caused by mutations in 23S rRNA

The antibiotic growth promoter avilamycin inhibits protein synthesis by binding to bacterial ribosomes. Here the binding site is further characterized on Escherichia coli ribosomes. The drug interacts with domain V of 23S rRNA, giving a chemical footprint at nucleotides A2482 and A2534. Selection of avilamycin-resistant Halobacterium halobium cells revealed mutations in helix 89 of 23S rRNA. Furthermore, mutations in helices 89 and 91, which have previously been shown to confer resistance to evernimicin, give cross-resistance to avilamycin. These data place the binding site of avilamycin on 23S rRNA close to the elbow of A-site tRNA. It is inferred that avilamycin interacts with the ribosomes at the ribosomal A-site interfering with initiation factor IF2 and tRNA binding in a manner similar to evernimicin.     

Ribosomal mutations in Streptococcus pneumoniae clinical isolates

Eleven clinical isolates of Streptococcus pneumoniae, isolated in Finland during 1996 to 2000, had an unusual macrolide resistance phenotype. They were resistant to macrolides and streptogramin B but susceptible, intermediate, or low-level resistant to lincosamides. No acquired macrolide resistance genes were detected from the strains. The isolates were found to have mutations in domain V of the 23S rRNA or ribosomal protein L4. Seven isolates had an A2059C mutation in two to four out of the four alleles encoding the 23S rRNA, two isolates had an A2059G mutation in two alleles, one isolate had a C2611G mutation in all four alleles, and one isolate had a 69GTG71-to-69TPS71 substitution in ribosomal protein L4.     

A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori.

We have developed a rapid PCR-oligonucleotide ligation assay that can discriminate single base substitutions that are associated with clarithromycin resistance in Helicobacter pylori. Susceptible isolates were wild type at positions 2143 and 2144 (cognate to 2058 and 2059 in Escherichia coli), while 93% of the resistant isolates contained A-to-G mutations at either position and 7% of the isolates contained A-to-C mutations at position 2143. In addition, the MIC for 86% of the resistant isolates with an A2143 mutation was > or = 64 micrograms per ml, and that for 89% of the resistant isolates with an A2144 mutation was < or = 32 micrograms per ml.     

Differences in the Frequency of 23S rRNA Gene Mutations in Mycoplasma pneumoniae between Children and Adults with Community-Acquired Pneumonia: Clinical Impact of Mutations Conferring Macrolide Resistance

We investigated the frequency and clinical significance of macrolide resistance in adult and pediatric patients with community-acquired pneumonia from a Mycoplasma pneumoniae infection. The frequency of the A2063G mutation in the 23S rRNA gene was significantly higher in children than in adults (61.3% [19/31] and 13.3% [8/60], respectively; P < 0.001). Patients with macrolide-resistant M. pneumoniae infections showed a longer duration of fever (P = 0.021) and required a longer duration of antibiotic treatment (P = 0.007).     

Dissemination of 16S rRNA methylase-mediated highly amikacin-resistant isolates of Klebsiella pneumoniae and Acinetobacter baumannii in Korea

Novel 16S rRNA methylase-mediated high-level resistance to amikacin and arbekacin has been reported recently in clinical isolates of Gram-negative bacilli only from several countries. We tested amikacin- or arbekacin-nonsusceptible Gram-negative bacilli isolated in 2003 and 2005 at a tertiary-care hospital in Korea by polymerase chain reaction to detect 16S rRNA methylase genes. armA alleles were detected in 14 isolates of Klebsiella pneumoniae, 10 other species of Enterobacteriaceae, and 16 Acinetobacter baumannii, whereas the rmtB allele was detected in 1 K. pneumoniae isolate. The resistance 1st detected in 2003 persisted in 2005. 16S rRNA methylase-producing isolates were highly resistant to arbekacin and amikacin, and were mostly coresistant to levofloxacin. Most K. pneumoniae isolates also produced extended-spectrum beta-lactamases and plasmid-mediated AmpC beta-lactamases, and most A. baumannii isolates were nonsusceptible to carbapenems.     

Resistance phenotypes and genotypes of erythromycin-resistant Streptococcus pneumoniae isolates in Beijing and Shenyang, China

Of a total of 192 Streptococcus pneumoniae isolates, 149 (77.6%) were not susceptible to erythromycin. Of these 149 isolates, 117 (79.1%) contained the erm(B) gene, 16 (10.8%) contained the mef(A) gene, and 15 (10.1%) harbored both the erm(B) and mef(A) genes.     

质粒介导16S rRNA甲基化酶肺炎克雷伯菌临床分离株的检测及分子流行病学研究

目的 调查165 rRNA甲基化酶在肺炎克雷伯菌临床分离株中的流行情况.方法 收集我院2006年1月至2007年9月从临床标本中分离的肺炎克雷伯菌337株,所有菌株均为非重复株.菌种鉴定采用全自动微生物分析仪,庆大霉素、阿米卡星和妥布霉素的药敏试验采用琼脂稀释法.超广谱B内酰胺酶(ESBLs)检测采用美国临床和实验窒标准协会(CLSI)规定的纸片确证法.使用PCR检测16S rRNA甲基化酶基因、整合酶基因和ESBL基因.接合试验检测质粒的可转移性;脉冲场电泳分析菌株的同源性.结果 337株肺炎克雷伯菌对庆大霉素、妥布霉素和阿米卡星的耐药率分别为19.0%(64/337)、8.3%(28/337)和16.3%(55/337).21株16S rRNA甲基化酶基因阳性,阳性率为6.2%(21/337),其中13株rmtB阳性、3株armA阳性、5株rmtB和atmA同时阳性.所有16S rRNA甲基化酶基因阳性株对庆大霉素、妥布霉素和阿米卡星同时耐药且都为高度耐药(MICs≥256μL),21株甲基化酶基因阳性株有19株产ESBLs,ESBL基因主要为CTX-M-14-like、CTX-M-15-like和SHV-12-like.21株均为Ⅰ类整合酶基因阳性.13株通过接合试验把质粒传递给受体菌E. coliJ53.所有接合子Ⅰ类整合酶基因阳性、blaTEM-1基因阳性、产ESBLs及对庆大霉素、妥布霉素、阿米卡星和复方磺胺甲噁唑耐药,对其他抗菌药物敏感.接合子ESBL基因型与供菌一致.21株16S rRNA甲基化酶基因阳性株经脉冲场凝胶电泳(PFGE)分成14个基因型,主要为A型和Ⅰ型.结论 armA和rmtB型16S rRNA甲基化酶基因已经在肺炎克雷伯菌中播散,既可通过克隆株播散也可通过接合性质粒在不同菌株间播散.     

Mutation in 23S rRNA responsible for resistance to 16-membered macrolides and streptogramins in Streptococcus pneumoniae

Streptococcus pneumoniae clinical isolate BM4455 was resistant to 16-membered macrolides and to streptogramins. This unusual resistance phenotype was due to an A(2062)C (Escherichia coli numbering) mutation in domain V of the four copies of 23S rRNA.     

Time-kill study of the activity of telithromycin against macrolide-resistant Streptococcus pneumoniae Isolates with 23S rRNA mutations and changes in ribosomal proteins L4 and L22

By use of a time-kill methodology, the antipneumococcal activity of telithromycin was determined against macrolide-resistant S. pneumoniae isolates having mutations in the 23S rRNA gene and changes in the ribosomal proteins L4 and L22. Telithromycin had MICs ranging between 0.03 and 0.25 microg/ml and was bactericidal against four of seven strains after 24 h at two times the MIC.